RU2189251C2 - Химические соединения - Google Patents

Химические соединения Download PDF

Info

Publication number
RU2189251C2
RU2189251C2 RU97112396/14A RU97112396A RU2189251C2 RU 2189251 C2 RU2189251 C2 RU 2189251C2 RU 97112396/14 A RU97112396/14 A RU 97112396/14A RU 97112396 A RU97112396 A RU 97112396A RU 2189251 C2 RU2189251 C2 RU 2189251C2
Authority
RU
Russia
Prior art keywords
enzyme
dna
cells
host
minutes
Prior art date
Application number
RU97112396/14A
Other languages
English (en)
Russian (ru)
Other versions
RU97112396A (ru
Inventor
Кристофер Джон ТЭЙЛОРСОН (GB)
Кристофер Джон ТЭЙЛОРСОН
Хендрикус Йоганнес ЭГЕЛЬТЕ (NL)
Хендрикус Йоганнес ЭГЕЛЬТЕ
Антонио ТАРРАГОНА-ФИОЛ (ES)
Антонио ТАРРАГОНА-ФИОЛ
Брайан Роберт РАБИН (GB)
Брайан Роберт РАБИН
Фрэнсис Томас БОЙЛ (GB)
Фрэнсис Томас БОЙЛ
Джон Фредерик ХЕННЭМ (GB)
Джон Фредерик ХЕННЭМ
Дэвид Чарльз БЛЭЙКИ (GB)
Дэвид Чарльз БЛЭЙКИ
Питер Роберт МЭРШЭМ (GB)
Питер Роберт МЭРШЭМ
Дэвид Уилль м ХИТОН (GB)
Дэвид Уилльям ХИТОН
Дэвид Хью ДЭВИС (GB)
Дэвид Хью ДЭВИС
Энтони Майкл СЛЭЙТЕР (GB)
Энтони Майкл СЛЭЙТЕР
Лоран Франсуа Андре ЭННЕКЭН (FR)
Лоран Франсуа Андре ЭННЕКЭН
Original Assignee
Зенека Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2189251(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9426192.2A external-priority patent/GB9426192D0/en
Priority claimed from GBGB9516810.0A external-priority patent/GB9516810D0/en
Application filed by Зенека Лимитед filed Critical Зенека Лимитед
Publication of RU97112396A publication Critical patent/RU97112396A/ru
Application granted granted Critical
Publication of RU2189251C2 publication Critical patent/RU2189251C2/ru

Links

Images

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Developing Agents For Electrophotography (AREA)
RU97112396/14A 1994-12-23 1995-12-21 Химические соединения RU2189251C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9426192.2A GB9426192D0 (en) 1994-12-23 1994-12-23 Chemical compounds
GB9426192.2 1994-12-23
GBGB9516810.0A GB9516810D0 (en) 1995-08-16 1995-08-16 Chemical compounds
GB9516810.0 1995-08-16

Publications (2)

Publication Number Publication Date
RU97112396A RU97112396A (ru) 1999-06-27
RU2189251C2 true RU2189251C2 (ru) 2002-09-20

Family

ID=26306259

Family Applications (1)

Application Number Title Priority Date Filing Date
RU97112396/14A RU2189251C2 (ru) 1994-12-23 1995-12-21 Химические соединения

Country Status (23)

Country Link
US (1) US5985281A (https=)
EP (1) EP0806964B1 (https=)
JP (1) JP3805365B2 (https=)
KR (1) KR100270650B1 (https=)
CN (1) CN1095677C (https=)
AT (1) ATE222124T1 (https=)
AU (1) AU701916B2 (https=)
BR (1) BR9510490B1 (https=)
CA (1) CA2205091A1 (https=)
CZ (1) CZ195297A3 (https=)
DE (1) DE69527805T2 (https=)
ES (1) ES2181805T3 (https=)
FI (1) FI972683L (https=)
HU (1) HUT77450A (https=)
IL (1) IL116511A0 (https=)
MX (1) MX9704575A (https=)
NO (1) NO972882L (https=)
NZ (1) NZ297529A (https=)
PL (1) PL184031B1 (https=)
RU (1) RU2189251C2 (https=)
SK (1) SK80997A3 (https=)
TR (1) TR199501654A2 (https=)
WO (1) WO1996020011A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1193278A (zh) 1995-08-16 1998-09-16 曾尼卡有限公司 化合物
SG71046A1 (en) 1996-10-10 2000-03-21 Connector Systems Tech Nv High density connector and method of manufacture
AU6000698A (en) * 1997-02-14 1998-09-08 Zeneca Limited Proteins
GB9703201D0 (en) * 1997-02-15 1997-04-02 Zeneca Ltd Chemical compounds
GB9709421D0 (en) * 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
JP4616991B2 (ja) * 1998-09-18 2011-01-19 イミューノメディクス、インコーポレイテッド 化学療法剤の標的特異的な毒性を増加させるための方法および組成物
US6361774B1 (en) 1999-09-17 2002-03-26 Immunomedics, Inc. Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug
US20040117863A1 (en) * 1998-09-18 2004-06-17 Edge Michael D. Transgenically produced fusion proteins
EP1220864A4 (en) * 1999-09-17 2003-05-21 Genzyme Transgenics Corp TRANSGENICALLY PRODUCED FUSION PROTEINS
US7067148B2 (en) 2001-02-15 2006-06-27 King Pharmaceutical Research & Development, Inc. Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
BR0316643A (pt) * 2002-11-27 2005-10-11 Gtc Biotherapeutics Inc Anticorpos modificados estavelmente produzidos no leite e método de produzir os mesmos
US20080019905A9 (en) * 2005-02-18 2008-01-24 Strome Scott E Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
KR20080068089A (ko) * 2005-10-21 2008-07-22 지티씨바이오쎄라퓨틱스,인크. 항체 의존성 세포 독성 활성이 증강된 항체, 그 생산 및사용 방법
US20080031866A1 (en) * 2006-06-20 2008-02-07 Eichenbaum Gary M Method for modulating the pharmacokinetics and metabolism of a therapeutic agent
WO2007149827A2 (en) * 2006-06-20 2007-12-27 Janssen Pharmaceutica, N.V. Method for modulating the pharmacokinetics and metabolism of a therapeutic agent
EP2077991B1 (en) * 2006-10-03 2014-02-26 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of mustards and related compounds with very high skin penetration rates
GB0709333D0 (en) * 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
WO2009134389A2 (en) * 2008-05-01 2009-11-05 Gtc Biotherapeutics, Inc. An anti-cd137 antibody as an agent in the treatment of inflammatory conditions
US10745492B1 (en) * 2019-04-03 2020-08-18 Ark Diagnostics, Inc. Antibodies to symmetrically dimethylated arginine analytes and use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8705477D0 (en) * 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5632990A (en) * 1988-04-22 1997-05-27 Cancer Research Campaign Tech. Ltd. Treatment for tumors comprising conjugated antibody A5B7 and a prodrug
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
AU648015B2 (en) * 1989-01-23 1994-04-14 Akzo N.V. Site specific in-vivo activation of therapeutic drugs
US5433955A (en) * 1989-01-23 1995-07-18 Akzo N.V. Site specific in vivo activation of therapeutic drugs
AU674137B2 (en) * 1992-01-30 1996-12-12 Genzyme Limited Chiral synthesis with modified enzymes
GB9323429D0 (en) * 1993-11-12 1994-01-05 Wellcome Found Therapy
US5389537A (en) * 1994-01-21 1995-02-14 Wisconsin Alumni Research Foundation Nuclease having altered specificity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bosslet et.al. "Tumor-selective predrud...", Cancer Res., 1994, v/54, p/2151-2559. *

Also Published As

Publication number Publication date
JP3805365B2 (ja) 2006-08-02
IL116511A0 (en) 1996-07-23
HUT77450A (hu) 1998-04-28
CZ195297A3 (en) 1997-12-17
US5985281A (en) 1999-11-16
AU701916B2 (en) 1999-02-11
PL184031B1 (pl) 2002-08-30
JPH10511547A (ja) 1998-11-10
MX9704575A (es) 1997-10-31
NO972882D0 (no) 1997-06-20
FI972683A0 (fi) 1997-06-19
FI972683A7 (fi) 1997-06-19
KR100270650B1 (ko) 2000-11-01
PL320964A1 (en) 1997-11-24
TR199501654A2 (tr) 1996-07-21
NO972882L (no) 1997-08-19
ATE222124T1 (de) 2002-08-15
WO1996020011A1 (en) 1996-07-04
FI972683L (fi) 1997-06-19
BR9510490B1 (pt) 2010-10-05
ES2181805T3 (es) 2003-03-01
CA2205091A1 (en) 1996-07-04
CN1095677C (zh) 2002-12-11
DE69527805D1 (de) 2002-09-19
BR9510490A (pt) 1998-01-13
TR199501654A3 (https=) 1996-07-21
NZ297529A (en) 1999-07-29
EP0806964B1 (en) 2002-08-14
CN1171054A (zh) 1998-01-21
DE69527805T2 (de) 2003-04-24
AU4269796A (en) 1996-07-19
SK80997A3 (en) 1998-02-04
EP0806964A1 (en) 1997-11-19

Similar Documents

Publication Publication Date Title
RU2189251C2 (ru) Химические соединения
EP2046375B1 (en) Methods and compositions for the selective activation of protoxins through combinatorial targeting
AU719513B2 (en) Monoclonal antibody to CEA, conjugates comprising said antibody, and their therapeutic use in an adept system
US9809654B2 (en) Targeted CD1d molecules
EP1551448B1 (en) Targeted cd1d molecules
KR20220124762A (ko) 펩티드 함유 링커를 갖는 부위 특이적 항체-약물 접합체
IE83238B1 (en) Fusion proteins with monoclonal antibody, linker and beta glucuronidase for prodrug activation; preparation and use thereof
CN114729353A (zh) 经工程化的肿瘤选择性蛋白的表达
US6436691B1 (en) Chemical compounds
JP2000504218A (ja) リガンド指令酵素プロドラッグ療法
US20050158324A1 (en) Methods of therapy and diagnosis using targeting of cells that express BCLP polypeptides
JP2002512774A (ja) 組換えオンコナーゼと、その化学的接合体および融合タンパク質
KR20000010771A (ko) Cea에 대한 모노클로널 항체, 이 항체를 함유하는 접합체 및adept계에서의 치료적 용도

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner
PC4A Invention patent assignment

Effective date: 20070328

PC4A Invention patent assignment

Effective date: 20070604

MM4A The patent is invalid due to non-payment of fees

Effective date: 20121222